Mon, Dec 29, 2014, 9:10 AM EST - U.S. Markets open in 20 mins.

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • epix_gets_fda_approval epix_gets_fda_approval Feb 14, 2011 4:08 PM Flag

    Very rare Adam Feuerstein NOT badmouthing EXEL

    adam feuerstein: the EXEL presentaton room is a locked iron box below the nuclear fallout shelter. this may not work for long. sorry. i'm taking notes and can update later.


    Monday February 14, 2011 11:32 adam feuerstein
    11:33 [Comment From biotechbaumer biotechbaumer : ]
    I think EXEL is up almost 100% in the past few months with no news, whats going on??!

    Monday February 14, 2011 11:33 biotechbaumer
    11:34 adam feuerstein: EXEL" is the cabozantinib company," says CEO.

    Thursday -- updated data will be released at 4 pm. aniticpate 100 evaluable patients, with approx 50 patients with mets on bone scan. expect duration follow up of approx 4 months.

    the abstract comes out tomorrow but those data are preliminary. exel will have more data on thursday.

    Monday February 14, 2011 11:34 adam feuerstein
    11:36 adam feuerstein: Cabozantinib = XL184 FYI. i will use "cabo" for short

    ASCO annual meeting -- submitted abstracts in variety of cancers, including ovarian and prostate.

    readout of top line data from ph 3 data in medullary thyroid cancer expected in 2h 2011.

    Monday February 14, 2011 11:36 adam feuerstein
    11:37 adam feuerstein: cabo is a MET/VEGFR inhibitor. activity in 9 different tumor types. resolution of bone lesions on bone scans in 4 tumor types.

    Monday February 14, 2011 11:37 adam feuerstein
    11:38 adam feuerstein: cabo prostate data from last year == n= 99 patients 3 cPR and 2 uPR from 34 evaluable patients. Disease control rate of 71%

    Monday February 14, 2011 11:38 adam feuerstein
    11:39 adam feuerstein: cabo -- bone mets is unmet medical need. bone mets occur in 300K patients in the US annually. most prominent in prostate, breast, lung and multiple myeloma.

    Monday February 14, 2011 11:39 adam feuerstein
    11:40 [Comment From Guest Guest : ]
    Any sense of credibility of EXEL presenter & presentation?

    Monday February 14, 2011 11:40 Guest
    11:41 adam feuerstein: credibility not an issue with EXEL. room is packed.

    Monday February 14, 2011 11:41 adam feuerstein
    11:41 adam feuerstein: prostate cancer treatment is getting very crowded. interesting.

    Monday February 14, 2011 11:41 adam feuerstein
    11:42 [Comment From Guest2 Guest2 : ]
    EXEL CEO was on CNBC this morning and seemed confident

    Monday February 14, 2011 11:42 Guest2
    11:43 adam feuerstein: Question for later follow up: How does Amgen's Xgeva play here given its prostate cancer bone mets data?

    Monday February 14, 2011 11:43 adam feuerstein
    11:44 [Comment From Trez Trez : ]
    can you name any of the large tier 1 firms attending? Also, of those tier 1 firms, which is asking the most questions?

    Monday February 14, 2011 11:44 Trez
    11:45 adam feuerstein: No breakouts at this conference, just a lot of 1x1 meetings in addition to the presentations.

    Monday February 14, 2011 11:45 adam feuerstein
    11:45 [Comment From Guest Guest : ]
    Room more packed than other presentations? What does "crowded" mean re prostate cancer treatment?

    Monday February 14, 2011 11:45 Guest
    11:46 adam feuerstein: "crowded" means a lot of drugs in the prostate cancer treatment pipeline. some compete against each other, some do not -- yet. It's a very fluid situation. docs have a lot more treatment choices -- or will soon.

    Means you can't think about EXEL in a vacuum but must consider data from competing drugs.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Feuerstein has put EXEL on center stage. He will obviously be listening on the 17th and will probably publish his opinion on Friday, the 18th. If the rally is to continue, a positive review by AF is pretty much a requirement. After Thursday, we enter a no news period (barring surprises) until topline MTC or ASCO in June. To continue the rally, we need positive press and recommendations from mainstream analysts. If AF joins David Miller, then Cramer will follow soon after.

      I find two similar comments from both AF and DM really interesting. Both mentioned how they very much prefer EXEL's new focused strategy as compared to prior years cranking out 3-4 IND's per year. The ironic part to me, is that it was EXEL's shotgun approach developing two MET/VEGF inhibitors that allowed 184 to drop in their lap and it was that continued shotgun strategy testing 184 in 12 different tumor types that enabled them to stumble on the bone scan resolution phenomenon. The focused strategy can't work unless you have an effective drug on which to focus. But they do have a point, while the shotgun approach "worked," I have to admit that EXEL focused on 184 today is more investment worthy than it was 12 months ago.

      • 2 Replies to erniewerner
      • Wow...can you imagine what would happen in AF said something "negative" in order to snap up some shares? Nawwww, things like that don't happen...it would be ILLEGAL!! LMAO.

        I couldn't imagine something "negative" coming out, causing the stock to suddenly spike down HARD while everyone and their mothers are expecting just the opposite. No WAY that could happen.

      • I'd say it's taken EXEL to a different "stage" or "maturity" as far as biotechs go. They sure had a hellofa pipeline going through for quite some time, and I would really love to see them monetize XL184 and then use that money to develop the other compounds they still have ownership or partial ownership of. Wistful thinking perhaps, seems like all the great companies (Genentech in particular) get taken out when they get something truly wonderful going.

    • 4:27 adam feuerstein: EXEL is definitely interesting. i'm looking forward to seeing the '184 data on Thursday. I'm glad to see the company FOCUS on a single drug instead of being so scatter brained.

    • Monday February 14, 2011 11:45 adam feuerstein
      11:45 [Comment From Guest Guest : ]
      Room more packed than other presentations? What does "crowded" mean re prostate cancer treatment?

      Monday February 14, 2011 11:45 Guest
      11:46 adam feuerstein: "crowded" means a lot of drugs in the prostate cancer treatment pipeline. some compete against each other, some do not -- yet. It's a very fluid situation. docs have a lot more treatment choices -- or will soon.

      Means you can't think about EXEL in a vacuum but must consider data from competing drugs.

      Monday February 14, 2011 11:46 adam feuerstein
      11:47 adam feuerstein: EXEL -- thinks cabo targets 2 key cell types in met bone lesions compared to Amgen's Xgeva, which targets just one key cell type. Again, something to research later.

      Monday February 14, 2011 11:47 adam feuerstein
      11:52 adam feuerstein: EXEL looking at "longshot" approach to file cabo in prostate cancer in 2h 2011. sounds a bit aggressive to me but i understand the desire to push ahead as fast as possible. FDA very tough on accelerate approval these days.

      Monday February 14, 2011 11:52 adam feuerstein
      11:53 adam feuerstein: more likely is ph 3 program in prostate cancer starting in 2012.. prevention of bone mets, symptomatic bone pain relief, extend overall survival..

      Monday February 14, 2011 11:53 adam feuerstein
      11:54 adam feuerstein: EXEL is holding an investor event on thursday to fully update with the cabo data and future plans. sounds like that's the more impt investor meeting than the quick summary we're getting today.

      Monday February 14, 2011 11:54 adam feuerstein
      11:54 [Comment From stillfeelgone stillfeelgone : ]
      prostate in 2H 2011? Thats news.

      Monday February 14, 2011 11:54 stillfeelgone
      11:55 adam feuerstein: "longshot" the CEO said "longshot" keep that in mind.

      Monday February 14, 2011 11:55 adam feuerstein
      11:56 adam feuerstein: lunch break!!!!

      Monday February 14, 2011 11:56 adam feuerstein
      12:20 adam feuerstein: my roast beef sandwich box lunch only gets a C.

      Monday February 14, 2011 12:20 adam feuerstein
      12:23 adam feuerstein: Not a bad morning -- MDVN and EXEL were the tops.

 
EXEL
1.33Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.